Fabian Hansen

TERN is a AI-Recruitment platform on a mission to address critical workforce shortages in the UK, EU, US and GCC, thats now over 40 million short, translating into a $1Tn category. TERN is a full-stack solution to source and relocate top-tier medical and engineering talent from India, North Africa, South Africa and Central Asia. Our approach ensures a seamless, ethical, and transparent migration process, drastically cutting complexity and shaving cost for healthcare systems. TERN stands as the bridge between high-potential international professionals and European/GCC institutions, fostering a global workforce that is skilled, diverse, and professionally equipped.

With a dedicated focus on Latin America, we acquire and scale e-commerce merchants that sell outstanding products and have excellent customer ratings. A passion for brands and products combined with depths of expertise and a strong capital base allows us to significantly scale acquired merchants and help them reach the next stage. Valoreo is a technology-driven consumer holding that creates long-term value by focusing on up-and-coming brands, specific product niches and outstanding customer satisfaction. We are one of Latin America’s fastest growing startups backed by top-tier institutional investors and international business angels. Our experienced and dynamic team is guided by the vision to build Latin America’s premier brands and excited about new challenges and growth.

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

We are a clinical-stage biotechnology company revolutionizing the discovery and development process for novel peptide therapeutics for patients with serious and life-threatening diseases. Combining the untapped potential of peptide biology with the power of machine learning, we strive to scale our drug design approach and usher in the next generation of peptide therapeutics through precision engineering and design. Our lead peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective currently being investigated in clinical studies as a potential treatment for prosthetic joint infection, a historically difficult-to-treat condition with a severe unmet need.

Bi Continental (US/European Union) Quantum AI Powered Stealth BioTech Startup

AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments.

From Entrepreneurs to Entrepreneurs. Today Razor Group is one of Europe’s fastest growing and most profitable unicorns. We are building a global eCommerce powerhouse by prioritizing operational efficiency through the use of accurate scaling and technology. With a recent Series C raise of over €80 million and ongoing strategic acquisitions, Razor Group is poised to make a significant impact on the e-commerce industry. Our vision is becoming a reality!

Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur and investor Christian Angermayer. At our core, we are driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. As entrepreneurs at heart, we pride ourselves on being hands-on, reliable, and long-term partners—committed to supporting exceptional founders of companies as well as emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. We apply a global multi-strategy investment approach, with a primary focus on the US, and teams across New York, London, Berlin, Abu Dhabi, and Malta. Our efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers we have stakes in currently manage approximately $5 billion in external capital. Follow Christian and Apeiron on X: @C_Angermayer and @ApeironInvests. For media, event and podcast queries please email media@apeiron-investments.com.

TERN is a AI-Recruitment platform on a mission to address critical workforce shortages in the UK, EU, US and GCC, thats now over 40 million short, translating into a $1Tn category. TERN is a full-stack solution to source and relocate top-tier medical and engineering talent from India, North Africa, South Africa and Central Asia. Our approach ensures a seamless, ethical, and transparent migration process, drastically cutting complexity and shaving cost for healthcare systems. TERN stands as the bridge between high-potential international professionals and European/GCC institutions, fostering a global workforce that is skilled, diverse, and professionally equipped.

With a dedicated focus on Latin America, we acquire and scale e-commerce merchants that sell outstanding products and have excellent customer ratings. A passion for brands and products combined with depths of expertise and a strong capital base allows us to significantly scale acquired merchants and help them reach the next stage. Valoreo is a technology-driven consumer holding that creates long-term value by focusing on up-and-coming brands, specific product niches and outstanding customer satisfaction. We are one of Latin America’s fastest growing startups backed by top-tier institutional investors and international business angels. Our experienced and dynamic team is guided by the vision to build Latin America’s premier brands and excited about new challenges and growth.

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecules potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloys affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/

We are a clinical-stage biotechnology company revolutionizing the discovery and development process for novel peptide therapeutics for patients with serious and life-threatening diseases. Combining the untapped potential of peptide biology with the power of machine learning, we strive to scale our drug design approach and usher in the next generation of peptide therapeutics through precision engineering and design. Our lead peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective currently being investigated in clinical studies as a potential treatment for prosthetic joint infection, a historically difficult-to-treat condition with a severe unmet need.